- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Efsitora improves HbA1c control compared to degludec in Japanese adults.
Última actualización 17 de julio de 2026
Key finding
Mean HbA1c decreased from 8.04% to 6.63% with efsitora.
This study compared once-weekly efsitora to once-daily degludec in reducing HbA1c levels in Japanese adults with type 2 diabetes, finding comparable efficacy.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared once-weekly efsitora to once-daily degludec in reducing HbA1c levels in Japanese adults with type 2 diabetes, finding comparable efficacy.
Clinical relevance
This research is significant as it provides evidence that efsitora, a less frequent dosing option, can effectively manage blood sugar levels in individuals with type 2 diabetes. This may improve adherence to treatment regimens, potentially leading to better long-term health outcomes for patients. Understanding the effectiveness of efsitora compared to established treatments like degludec can help clinicians make informed decisions about diabetes management.
Keep in mind
Unclear effectiveness due to lack of statistical significance in some outcomes Limited generalizability to populations outside Japan Potential unmeasured confounders affecting results
Published in
Referencia de la Revista
Publication details and source links for this paper.
Arihiro K, Mariko I, Yasushi T, Risa N, Hirotaka W. Once-weekly efsitora is comparable to once-daily degludec in reducing HbA1c in Japanese adults with T2D. Diabetes Therapy. 2026;17(5):771-785. doi:10.1007/s13300-026-01860-w
Efectos Principales
Efsitora reduced mean HbA1c from 8.04% to 6.63% (decrease of -1.41%)
Degludec reduced mean HbA1c from 8.00% to 6.64% (decrease of -1.36%)
Time in target glucose range was similar between efsitora and degludec
Rates of level 2/3 hypoglycemia were low for both treatments
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Efsitora, Insulin degludec and HbA1c, Severe hypoglycemia, Time in range.
This study contributes evidence to
Primary intervention
Efsitora
Primary outcomes
- HbA1c
- Severe hypoglycemia
- Time in range
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
5
Evidence pairs
652
Related studies
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Insulin Therapies and HbA1c
Evidencia relacionada
Relación de evidencia
Insulin Therapies and Hypoglycemia
Guardar evidencia
Tema de evidencia
Hypoglycemia
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- Efsitora and degludec both significantly lowered HbA1c levels by approximately 1.4%
- Time in target glucose range was comparable between both treatments
- Low incidence of severe hypoglycemia was reported for both medications
A quién se aplica
- Japanese adults diagnosed with type 2 diabetes
- Patients requiring insulin therapy for blood sugar management
Tener en Cuenta
- Results may not be applicable to non-Japanese populations
- Further studies needed to confirm long-term safety and efficacy
- Study design limitations may affect the interpretation of effectiveness
Entre Líneas
- Unclear effectiveness due to lack of statistical significance in some outcomes
- Limited generalizability to populations outside Japan
- Potential unmeasured confounders affecting results
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Efsitora and HbA1c, Efsitora and Hypoglycemia.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Efsitora → HbA1c
Medications
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Efsitora → Hypoglycemia
Medications
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Efsitora Evidence Hub
All studies on Efsitora
Contributes to Efsitora evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
Measures HbA1c as a key outcome.
Hypoglycemia Evidence Hub
All studies measuring Hypoglycemia
Measures Hypoglycemia as a key outcome.
Recent Diabetes Research
Latest published studies
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Efsitora and HbA1c
1 results
All studies on Efsitora and Severe hypoglycemia
1 results
All studies on Efsitora
1 results
All studies measuring HbA1c
1 results
All studies measuring Severe hypoglycemia
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Insulin Therapies improve HbA1c?
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin Therapies affect hypoglycemia?
Insulin Therapies may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 4 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Efsitora improve HbA1c?
Efsitora appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Efsitora affect severe hypoglycemia?
Current evidence does not show a clear benefit of Efsitora for Severe hypoglycemia.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.
